Home > Cardiology > AHA 2020 > Heart Failure > Omecamtiv mecarbil improves outcomes in HFrEF-patients

Omecamtiv mecarbil improves outcomes in HFrEF-patients

Presented By
Prof. John Teerlink, University of California, San Francisco, USA
AHA 2020
In patients with heart failure with reduced ejection fraction (HFrEF), treatment with the selective cardiac myosin-activator omecamtiv mecarbil resulted in a lower risk of a composite of heart failure and cardiovascular events, according to results from the placebo-controlled GALACTIC-HF trial [1]. Prof. John Teerlink (University of California, San Francisco, USA) presented the results of the GALACTIC-HF (NCT02929329) trial, which were simultaneously published in the New England Journal of Medicine [2]. GALACTIC-HF is the first trial to test the hypothesis that selectively improving cardiac function with omecamtiv mecarbil improves outcomes in patients with HFrEF, meaning a decrease in the risk of cardiovascular death, prevention of clinical heart failure events, and improvement of symptoms. Participants were aged 18–85 years with New York Heart ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on